Agios Pharmaceuticals (NASDAQ:AGIO)

CAPS Rating: 3 out of 5

Results 1 - 8 of 8

Recs

0
Member Avatar marsuculix (64.41) Submitted: 6/22/2015 5:09:51 AM : Outperform Start Price: $100.65 AGIO Score: +11.90

two major catalysts coming in 2015 and 2016...

Recs

1
Member Avatar PieMan15 (53.11) Submitted: 2/17/2015 3:01:40 PM : Outperform Start Price: $109.70 AGIO Score: +2.01

The company has some promising and innovate cancer drugs. Possibly a potential take-over candidate as well.

Recs

1
Member Avatar sullyz0r (84.89) Submitted: 11/26/2014 10:43:23 AM : Outperform Start Price: $99.67 AGIO Score: +10.82

A "rich get richer" pick. Valuation is probably stretched at these levels, but the company is ripe for an eventual takeover.

Recs

1
Member Avatar jeepdrew2 (69.65) Submitted: 9/27/2014 6:59:42 PM : Outperform Start Price: $49.25 AGIO Score: +120.99

This biotech is the real deal. Just wait... picture another ICPT swing.

Recs

1
Member Avatar pchop123 (80.78) Submitted: 8/6/2014 4:47:21 PM : Outperform Start Price: $37.65 AGIO Score: +185.88

volatile but worth the ride

Recs

3
Member Avatar zzlangerhans (99.83) Submitted: 5/16/2014 5:28:42 PM : Outperform Start Price: $31.93 AGIO Score: +235.18

Agios has been a fun stock this spring, maintaining high volatility despite the heavy smog crushing the biopharma sector. In April the stock spiked as high as 48 after the company reported several complete and incomplete remissions from a phase I trial of mutated IDH2 inhibitor AG-221. The stock couldn't maintain that level, withering under the onslaught of "just phase I data" naysayers. Of course, some stocks like Pharmacyclics pop on phase I data and never look back. Agios also has several other compounds in the clinic including the mutated IDH2 inhibitor AG-120 in phase I for both hematologic malignancies and advanced solid tumors, and RBC pyruvate kinase activator AG-348 in phase I for pyruvate kinase deficiency. The current market cap of a billion isn't exactly pocket change, nor is it extravagant for a biopharma with two independent proprietary platforms and a solid partnership with Celgene. The zzporte portfolio has 100 shares at 36 and may continue to build below 30.

Recs

0
Member Avatar portefeuille (99.67) Submitted: 4/22/2014 10:29:33 AM : Outperform Start Price: $33.75 AGIO Score: +216.44

I have 20 AGIO shares in my private (i.e. non-zzporte) portfolio.

Recs

1
Member Avatar ptanabe (75.99) Submitted: 8/1/2013 4:00:20 PM : Outperform Start Price: $27.44 AGIO Score: +279.77

rc - celg backed

Results 1 - 8 of 8

Featured Broker Partners


Advertisement